DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

GB1211

Generic Name: GB1211

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₁₆BrF_₃N_₄O_₄S

CAS Number: 1978336-95-6

Unique Ingredient Identifier: 94EN2E6BLW

Overview

GB1211 is an orally active galectin-3 (Gal-3) inhibitor.

Background

GB1211 is an orally active galectin-3 (Gal-3) inhibitor.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

Phase 2

Recruiting

Posted: 2023/06/22

Sponsor:Providence Health & ...

A Study to Compare Pharmacokinetics of GB1211

Phase 1

Completed

Posted: 2023/02/28

Sponsor:Galecto Biotech AB

A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).

Phase 1

Active, not recruiting

Posted: 2022/02/15

Sponsor:Galecto Biotech AB

A Single and Repeat Dose Trial in Participants With Hepatic Impairment

Phase 1

Active, not recruiting

Posted: 2021/08/17

Sponsor:Galecto Biotech AB

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

Phase 1

Withdrawn

Posted: 2020/10/29

Sponsor:Galecto Biotech AB

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Galecto Shifts Focus to Oncology with Acquisition of Dual ENL-YEATS/FLT3 Inhibitor for AML Treatment

2 months ago

Galecto has completed a strategic pivot to oncology and liver diseases, acquiring global rights to GB3226, a novel dual ENL-YEATS and FLT3 inhibitor targeting multiple genetic subsets of acute myeloid leukemia.

Advancements in HER2-Mutant NSCLC Therapies: A Pipeline Overview

8 months ago

Several companies are actively developing novel therapies for HER2-mutant non-small cell lung cancer (NSCLC), indicating a robust pipeline.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy